Content generated by AI editorial engine. Editorially supervised by Sedat ANAK.
The median of 9 price targets is $220[FMP target], stock is $187, +17.4% vs the analyst consensus median. Q1 FY26 EPS $2.50 vs $2.37 estimate: beat (+5.5%)[FMP earnings]. Stock move on D+1: -0.5%.
A- — FMP rating [FMP ratings]. Form 4: unavailable[FMP Form 4].
Quick AnswerQuest Diagnostics Incorporated (DGX) Q2 consensus: revenue $3.0B[FMP est], EPS $2.83[FMP est]. 8 consecutive quarters of beat[FMP earnings].
Q1 FY26 EPS $2.50 vs $2.37 estimate: beat (+5.5%)[FMP]. Stock move on D+1: -0.5%[FMP D+1].
Watchlist
Revenue Growth
revenue_growth
Quest Diagnostics achieved revenue growth of over 9%, driven by clinical innovations, expansion into new clinical areas, and collaborations.
"During the first quarter, we grew revenues over 9%, almost entirely from organic revenue growth on broad-based demand for our clinical innovations, expansion into new clinical areas and collaborations with elite health care and consumer health organizations."
- James Davis, Chairman, Chief Executive Officer and President - Q1 FY26 Earnings Call - April 21, 2026
Eps Growth
eps_growth
Quest Diagnostics grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from the deployment of automation and AI across its operations.
"In addition, we grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI across our operations both in and outside our labs."
- James Davis, Chairman, Chief Executive Officer and President - Q1 FY26 Earnings Call - April 21, 2026
Ai Customer Service
ai_customer_service
Quest Diagnostics boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses.
"As one example, we boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses."
- James Davis, Chairman, Chief Executive Officer and President - Q1 FY26 Earnings Call - April 21, 2026
Ai Companion Engagement
ai_companion_engagement
Patients have engaged Quest AI Companion approximately 350,000 times since Quest Diagnostics rolled it out to users of its MyQuest app in the first quarter.
"Patients have engaged Quest AI Companion approximately 350,000 times since we rolled it out to users of our MyQuest app in the first quarter."
- James Davis, Chairman, Chief Executive Officer and President - Q1 FY26 Earnings Call - April 21, 2026
Stock Expert AI - Methodology
Historical V1 earnings-model score (archived, May 9, 2026) — not the current MoonshotScore. Current MoonshotScore: DGX stock page
multi-pillar methodology. Cash Runway strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Buffett), 1 bearish (Ken Griffin), 3 neutral (Jim Simons, Klarman, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
Q1 FY26 (April 21, 2026) EPS $2.50 vs $2.37 estimate: beat (+5.5%)[FMP]. Stock move on D+1: -0.5%[FMP D+1].
Q1 FY26 EPS $2.50 vs $2.37 estimate: beat (+5.5%)[FMP]. Stock move on D+1: -0.5%[FMP].
No RPO/backlog concentration disclosed in Q1 earnings call.
Q1 CapEx $114.0M[FMP cashflow]. Q1 op margin 13.8%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Tuesday evening. The framework is ready on this page: Q2 EPS threshold $2.83[FMP], CapEx threshold "below $114.0M". Two anchors, three scenarios.
Comparison Stock Expert AI is free today — no credit card.
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 7-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This Quest Diagnostics Incorporated (DGX) Q2 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Quest Diagnostics Incorporated (DGX): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
Quest Diagnostics Incorporated (DGX): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
Quest Diagnostics Incorporated (DGX): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.